retatrutide triple agonist obesity trial 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type 2 diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Lilly orforglipron oral GLP-1 phase

Your Core Message: A medically supervised, affordable, results-driven weight loss program delivered 100% virtually

But it becomes even trickier when youre trying to connect ingredient benefits with the use of pharmaceutical treatments

There are no clinical trials on this patch format, no data testing this ingredient combo, and no human studies showing increased GLP-1 levels from this approach

GLP-1 drugs like semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda) do not appear on standard blood tests, drug screenings, or employment panels

If youve tried multiple approaches without lasting success, youre part of a much larger picture